Eversept Partners’ Return, AUM, and Holdings

The second largest holding the fund disclosed at the end of the third quarter was in R1 RCM Inc (NASDAQ:RCM), and after the fund has lowered its stake by 7% it counted 1.69 million shares valued $17.12 million. This is a healthcare revenue cycle management company that provides services to hospitals and various other healthcare institutions. Over the past 12 months, the company’s stock gained 81.8%, and at the moment of writing, it is trading at $8.09.

Among the biggest new additions to Eversept Partners’ portfolio were Merck & Co., Inc. (NYSE:MRK), Danaher Corporation (NYSE:DHR), and Xenon Pharmaceuticals Inc (NASDAQ:XENE). In Merck & Co, it has initiated a position that was valued $10.56 million, counting 147,800 shares, while in Danaher Corporation it has built a stake worth $3.87 million, which included 35,604 outstanding shares. It Xenon Pharmaceuticals it has established a valuable position of $2.77 million, by obtaining 209,739 shares. While Merck & Co are both pharmaceutical companies, Danaher Corporation is a more diversified company that produces a variety of professional medical, commercial and industrial products. Year to date, Danaher’s stock gained 7.97%, and it is currently trading at $99.81.

Among the biggest sold out positions in the third quarter were those in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In BioMarin Pharmaceutical, Everspet Partner sold out a stake that was valued at the end of the second quarter at $7.94 million, on the account of 84,257 shares. And, in Alnylam Pharmaceuticals the fund dropped its position which was worth around $6.25 million and counted 63,493 shares.

Disclosure: None

This article was originally published at Insider Monkey.